WhiteBook2_Part2 - 23

Results
Identifying Horizon 2020 cancer related research projects fell outside the scope of this study,
however we were able to examine research funding in relation to burden for cancers with
specific EuroSciVoc fields and corresponding DALY estimates. Figure 16 shows the
relationship between European Commission funding for Horizon 2020 cancer related
research projects and the number of DALYs per cancer in the EU in 2019. Of the digestive
cancers that were available to analyse, those that were associated with higher levels of
burden received higher levels of research funding. Colon and rectum cancer and pancreatic
cancer appeared to be under-funded in relation to burden compared with some of the other
cancers.
Figure 16.
Relationship between European Commission funding for Horizon 2020 cancer related research projects
and disease burden in the European Union (measured as Disability−Adjusted Lif e Years)
400,000,000
300,000,000
200,000,000
100,000,000
2,000,000
4,000,000
Number of DALYs
Colon and rectum cancer
Liver cancer
Pancreatic cancer
Bladder cancer
Breast cancer
Cervical cancer
Leukemia
Lung cancer
Prostate cancer
Source: authors' compilation using data e xtracted from CORDIS and GBD 2019 databases .
The grey line represents the level of funding that would be expected if funding was proportional to disease burden.
DALYs for lung cancer categor y include tracheal, bronchus, and lung cancer.
Skin cancer
6,000,000
White Book 2: Part 2
20
Euros
WhiteBook2_Part2

Table of Contents for the Digital Edition of WhiteBook2_Part2
